Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.78 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.78 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.78 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.78 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.78 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.78 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30301395 | 0.83 | GRIN2D (0.79) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2195472 | 0.83 | GRIN2D (0.79) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL13174675 | 0.82 | AKR1C3 (0.70) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7159340 | 0.81 | MEN1 (0.71) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7157967 | 0.80 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4815921 | 0.80 | GRIN2D (0.68) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7161597 | 0.79 | GRIN2D (0.71) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7177404 | 0.78 | GRIN2D (0.78) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7158932 | 0.77 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4813274 | 0.77 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172244-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-07-14 | — | — | US | disclosed |
| EP-2252586-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009105722-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172244-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GRIN2D 1516/4885GRIN3B 402/4885GRIN1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.